Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule.

Zom GG, Filippov DV, van der Marel GA, Overkleeft HS, Melief CJ, Ossendorp F.

Oncoimmunology. 2014 Jul 3;3(7):e947892. eCollection 2014.

2.

Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.

Zom GG, Willems MMJHP, Khan S, van der Sluis TC, Kleinovink JW, Camps MGM, van der Marel GA, Filippov DV, Melief CJM, Ossendorp F.

J Immunother Cancer. 2018 Dec 12;6(1):146. doi: 10.1186/s40425-018-0455-2.

3.

Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.

Zom GG, Khan S, Britten CM, Sommandas V, Camps MG, Loof NM, Budden CF, Meeuwenoord NJ, Filippov DV, van der Marel GA, Overkleeft HS, Melief CJ, Ossendorp F.

Cancer Immunol Res. 2014 Aug;2(8):756-64. doi: 10.1158/2326-6066.CIR-13-0223. Epub 2014 Apr 21.

4.

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.

Zom GG, Welters MJ, Loof NM, Goedemans R, Lougheed S, Valentijn RR, Zandvliet ML, Meeuwenoord NJ, Melief CJ, de Gruijl TD, Van der Marel GA, Filippov DV, Ossendorp F, Van der Burg SH.

Oncotarget. 2016 Oct 11;7(41):67087-67100. doi: 10.18632/oncotarget.11512.

5.

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.

Khan S, Bijker MS, Weterings JJ, Tanke HJ, Adema GJ, van Hall T, Drijfhout JW, Melief CJ, Overkleeft HS, van der Marel GA, Filippov DV, van der Burg SH, Ossendorp F.

J Biol Chem. 2007 Jul 20;282(29):21145-59. Epub 2007 Apr 26.

7.

Dual Synthetic Peptide Conjugate Vaccine Simultaneously Triggers TLR2 and NOD2 and Activates Human Dendritic Cells.

Zom GG, Willems MMJHP, Meeuwenoord NJ, Reintjens NRM, Tondini E, Khan S, Overkleeft HS, van der Marel GA, Codee JDC, Ossendorp F, Filippov DV.

Bioconjug Chem. 2019 Apr 17;30(4):1150-1161. doi: 10.1021/acs.bioconjchem.9b00087. Epub 2019 Mar 26.

PMID:
30865430
8.

Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.

Varypataki EM, van der Maaden K, Bouwstra J, Ossendorp F, Jiskoot W.

AAPS J. 2015 Jan;17(1):216-26. doi: 10.1208/s12248-014-9686-4. Epub 2014 Nov 12.

9.

Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.

Rahimian S, Fransen MF, Kleinovink JW, Christensen JR, Amidi M, Hennink WE, Ossendorp F.

J Control Release. 2015 Apr 10;203:16-22. doi: 10.1016/j.jconrel.2015.02.006. Epub 2015 Feb 7.

PMID:
25660830
10.

Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.

Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R.

Immunol Rev. 2002 Oct;188:177-82.

PMID:
12445291
11.

Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.

Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, Figdor CG, Adema GJ.

Cancer Res. 2000 Dec 15;60(24):6995-7001.

12.

Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.

Thomann JS, Heurtault B, Weidner S, Brayé M, Beyrath J, Fournel S, Schuber F, Frisch B.

Biomaterials. 2011 Jul;32(20):4574-83. doi: 10.1016/j.biomaterials.2011.03.015. Epub 2011 Apr 7.

PMID:
21474175
13.

Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide.

Shen KY, Song YC, Chen IH, Chong P, Liu SJ.

Hum Vaccin Immunother. 2014;10(11):3241-50. doi: 10.4161/hv.29275.

14.

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA.

Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23.

PMID:
9815296
15.

A novel multi-epitope peptide vaccine against cancer: an in silico approach.

Nezafat N, Ghasemi Y, Javadi G, Khoshnoud MJ, Omidinia E.

J Theor Biol. 2014 May 21;349:121-34. doi: 10.1016/j.jtbi.2014.01.018. Epub 2014 Feb 7.

PMID:
24512916
16.

Immunodominance across HLA polymorphism: implications for cancer immunotherapy.

Kim CJ, Parkinson DR, Marincola F.

J Immunother. 1998 Jan;21(1):1-16. Review.

PMID:
9456431
17.

Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus.

Hiranuma K, Tamaki S, Nishimura Y, Kusuki S, Isogawa M, Kim G, Kaito M, Kuribayashi K, Adachi Y, Yasutomi Y.

J Gen Virol. 1999 Jan;80 ( Pt 1):187-93.

PMID:
9934701
18.

Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects.

Indrová M, Reinis M, Bubeník J, Jandlová T, Bieblová J, Vonka V, Velek J.

Folia Biol (Praha). 2004;50(6):184-93.

19.

Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.

Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H.

J Transl Med. 2007 Feb 12;5:10.

20.

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens.

Jäeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M, Knuth A.

Int J Cancer. 1996 Apr 10;66(2):162-9.

Supplemental Content

Support Center